BLISS BIOPHARMACEUTICAL TO PRESENT DATA ON BB-1701 COHORT EXPANSION OF PHASE I STUDY AT 2023 ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM

Hangzhou, China, December 6, 2023 -- Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (“BlissBio”), a clinical-stage biopharmaceutical company developing differentiated antibody-drug conjugate (ADC) therapeutics, announced today that BB-1701 Cohort Expansion of Phase I study data will be presented at the 2023 Annual San Antonio Breast Cancer Symposium (2023 SABCS), to be held from December 5 to 9, 2023.

At this meeting, there will be an oral presentation on safety, tolerability, pharmacokinetics, and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2 Low Breast Cancer.

In April 2023, BlissBio and Eisai Co., Ltd (Headquarters: Tokyo, “Eisai”) entered into a clinical trial collaboration for BB-1701, and BlissBio commits to working with Eisai to advance the development of BB-1701 for the benefit of patients worldwide.

Abstract Title: Report on cohort expansion of phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2 low breast cancer　

Session Number: RF02-05

Session Title: Rapid Fire Session 2: Mini-Oral Presentations

Session Date and Time: 12:00pm-12:45pm, December 7, 2023

About BB-1701  

BB-1701 is an innovative ADC developed by BlissBio consisting of anti-HER2 antibody and eribulin. It is designed to provide a safer and more effective treatment regimen for patients with locally advanced/metastatic HER2 expressing solid tumors and expected to have multiple market prospects for application in various tumor indications. BB-1701 has unique mechanism of action (MOA) including potent bystander effect and immunogenic cell death (ICD) activity. BB-1701 is being used to conduct Phase I/II international clinical trials both in China and US.

About Bliss Biopharmaceutical (Hangzhou) Co., Ltd 

Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (“BlissBio”), is a clinical-stage biotech company dedicated to discovery, development and commercialization of anti-tumor biotherapeutics, founded by pharmaceutical veterans in 2017 in Hangzhou, Zhejiang province. BlissBio has established a unique and patented technical platform, a rich ADC-focusing pipeline, and GMP manufacture capability that could support antibody and ADC production for both clinical development and early commercialization. BlissBio has been nominated as a national high-tech biopharmaceutical enterprise in China. With “Together, We Improve Human Health” as the core value, through international and domestic collaborations, BlissBio will continue to focus on innovative drugs to address unmet medical needs.

For more information please visit https://www.blissbiopharma.com

About Eisai Co., Ltd

Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as our human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.

In addition, our continued commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), is demonstrated by our work on various activities together with global partners.

For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on Twitter, LinkedIn and Facebook.

Media Inquiries

Bliss Biopharmaceutical (Hangzhou) Co., Ltd

TEL: +86-0571-86808367

E-mail: office@blissbiopharma.com